Skip to main content
. Author manuscript; available in PMC: 2013 Sep 3.
Published in final edited form as: J Neuropsychiatry Clin Neurosci. 2012 Summer;24(3):326–330. doi: 10.1176/appi.neuropsych.11090210

TABLE 2.

Results of a Multivariate Linear Regression, Including All Control Variables and Parkinson’s Disease Medication Usea

Proportion of Patients Taking B Standard Error β p
Constant 1.08 4.86 NS
Age, years 0.10 0.05 0.14 0.047
Female sex 2.30 1.01 −0.16 0.024
Education, years 0.23 0.16 −0.10 NS
Disease duration, months 0.00 0.01 0.01 NS
Beck Depression Inventory 3.279 0.41 0.57 <0.001
Carbidopa/Levodopa 82% 0.05 0.04 0.09 NS
Dopamine agonistsb 44% 1.14 0.93 −0.08 NS
Amantadine 16% 1.00 1.28 0.05 NS
Selegiline/Rasagiline 21% 2.59 1.19 −0.15 0.032
Memantine 3% 3.06 2.73 −0.07 NS
Entacapone 20% 0.62 1.18 0.04 NS
a

R2=0.45 (p<0.001); N=143.

b

Pramipexole, ropirinole, rotigotine.